These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37749332)

  • 1. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
    Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
    Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
    Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PNPLA3 variant I148M reveals protective effects toward hepatocellular carcinoma in mice via restoration of omega-3 polyunsaturated fats.
    Patsenker E; Thangapandi VR; Knittelfelder O; Palladini A; Hefti M; Beil-Wagner J; Rogler G; Buch T; Shevchenko A; Hampe J; Stickel F
    J Nutr Biochem; 2022 Oct; 108():109081. PubMed ID: 35691594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
    Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.
    Kim HS; Xiao X; Byun J; Jun G; DeSantis SM; Chen H; Thrift AP; El-Serag HB; Kanwal F; Amos CI
    JAMA Netw Open; 2022 Oct; 5(10):e2234221. PubMed ID: 36190732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
    Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    Caon E; Martins M; Hodgetts H; Blanken L; Vilia MG; Levi A; Thanapirom K; Al-Akkad W; Abu-Hanna J; Baselli G; Hall AR; Luong TV; Taanman JW; Vacca M; Valenti L; Romeo S; Mazza G; Pinzani M; Rombouts K
    J Hepatol; 2024 Jun; 80(6):941-956. PubMed ID: 38365182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis.
    BasuRay S; Wang Y; Smagris E; Cohen JC; Hobbs HH
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9521-9526. PubMed ID: 31019090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 I148M polymorphism and progressive liver disease.
    Dongiovanni P; Donati B; Fares R; Lombardi R; Mancina RM; Romeo S; Valenti L
    World J Gastroenterol; 2013 Nov; 19(41):6969-78. PubMed ID: 24222941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
    J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.
    Mitsche MA; Hobbs HH; Cohen JC
    J Biol Chem; 2018 May; 293(18):6958-6968. PubMed ID: 29555681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Targeting of the Signaling Controls of
    Schwartz BE; Rajagopal V; Smith C; Cohick E; Whissell G; Gamboa M; Pai R; Sigova A; Grossman I; Bumcrot D; Sasidharan K; Romeo S; Sehgal A; Pingitore P
    Cells; 2020 Oct; 9(10):. PubMed ID: 33036387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant.
    Leníček M; Šmíd V; Pajer P; Nazarova A; Dvořák K; Subhanová I; Brůha R; Vítek L
    Sci Rep; 2021 Oct; 11(1):20924. PubMed ID: 34686753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
    Doueiry C; Kappler CS; Martinez-Morant C; Duncan SA
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.
    Jönsson C; Bergram M; Kechagias S; Nasr P; Ekstedt M
    Scand J Gastroenterol; 2024 Jun; 59(6):737-741. PubMed ID: 38563432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.